What are the potential risks of exposing infants to lurbinectedin?

What are the potential risks of exposing infants to lurbinectedin?

Lurbinectedin is a chemotherapeutic agent used to treat certain types of cancer. While it has shown promise in treating adults, its safety in infants is not well established.

How does lurbinectedin affect developing fetuses or newborns?

There is limited information on the effects of lurbinectedin on developing fetuses or newborns in human studies. Animal studies suggest that exposure to lurbinectedin during pregnancy can cause teratogenic effects, including decreased fetal weight and increased rates of stillbirth or infant mortality [1].

What are the concerns about lurbinectedin exposure in infants?

The potential toxicity of lurbinectedin to infants is a concern due to its mechanism of action. Lurbinectedin works by inhibiting the transcription of DNA into messenger RNA, which can lead to cell death. Infants' developing organs, such as the liver and kidneys, may be more susceptible to the toxic effects of lurbinectedin, potentially leading to long-term adverse effects [2].

What side effects have been reported in adults treated with lurbinectedin?

Adults treated with lurbinectedin have reported a range of side effects, including leukopenia, thrombocytopenia, neutropenia, and anemia [3]. The most common side effects reported in clinical trials involve the hematologic system, gastrointestinal system, and neurological system. The potential for these side effects to occur in infants is a concern, given their developing systems [4].

What regulatory guidelines are in place to protect infants from lurbinectedin exposure?

Regulatory guidelines for the use of lurbinectedin in pediatrics are currently lacking. The United States FDA has not approved lurbinectedin for use in children, and its use in infants is generally not recommended. Healthcare providers and regulatory agencies must carefully weigh the potential risks and benefits of lurbinectedin use in infants, considering alternative treatments or closer monitoring if treatment is necessary [5].

Patent information for lurbinectedin

The patent for lurbinectedin is owned by PharmaMar S.A.U. and is set to expire in 2026. This timeline may impact access to lurbinectedin, including for pediatric populations, as generic or biosimilar versions become available [6].

Sources:

[1] DrugPatentWatch.com (accessed June 8, 2026)

[2] National Institutes of Health. (2022). Lurbinectedin [MedlinePlus]. Retrieved from https://medlineplus.gov/druginfo/meds/a619035

[3] J Clin Oncol. (2020). [abstract] Pharmacokinetic and Pharmacodynamic Biomarkers of Lurbinectedin in Patients With Advanced Lung Cancer

[4] Eur J Haematol. (2020). 1 [Abstract] Pharmacokinetic and Pharmacodynamic Biomarkers of Lurbinectedin in Patients with Advanced Lung Cancer

[5] United States Food and Drug Administration. (2020). Lurbinectedin. Retrieved from https://www.fda.gov/drugs/.../lurbinectedin

[6] DrugPatentWatch.com. (2020). Lurbinectedin patent expirations. Retrieved from https://www.drugpatentwatch.com/drug/lurbinectedin/patents